Dyadic International, Inc. (NASDAQ:DYAI - Get Free Report)'s share price crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $1.56 and traded as high as $1.99. Dyadic International shares last traded at $1.73, with a volume of 171,662 shares changing hands.
Analysts Set New Price Targets
Separately, HC Wainwright reissued a "buy" rating and set a $6.00 target price on shares of Dyadic International in a research note on Thursday, November 14th.
Check Out Our Latest Analysis on Dyadic International
Dyadic International Stock Performance
The company has a debt-to-equity ratio of 1.54, a quick ratio of 5.15 and a current ratio of 5.15. The company's 50 day simple moving average is $1.57 and its 200 day simple moving average is $1.39.
Dyadic International (NASDAQ:DYAI - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.06. The company had revenue of $1.96 million for the quarter, compared to analysts' expectations of $1.05 million. Dyadic International had a negative net margin of 188.09% and a negative return on equity of 149.16%. During the same quarter in the previous year, the company posted ($0.06) EPS. As a group, research analysts forecast that Dyadic International, Inc. will post -0.18 earnings per share for the current year.
Hedge Funds Weigh In On Dyadic International
A hedge fund recently raised its stake in Dyadic International stock. Chapin Davis Inc. grew its position in Dyadic International, Inc. (NASDAQ:DYAI - Free Report) by 2.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 868,301 shares of the biotechnology company's stock after buying an additional 21,000 shares during the quarter. Chapin Davis Inc. owned approximately 2.97% of Dyadic International worth $903,000 at the end of the most recent quarter. Institutional investors own 27.95% of the company's stock.
About Dyadic International
(
Get Free Report)
Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.
Featured Articles
Before you consider Dyadic International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dyadic International wasn't on the list.
While Dyadic International currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
